Is Mounjaro approved for PCOS? This is a question many women with polycystic ovary syndrome are asking as they seek effective treatments for this complex metabolic and reproductive condition. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist that has shown remarkable results in type 2 diabetes management and weight loss. However, its regulatory status for PCOS remains unclear to many patients. Understanding what Mounjaro is licensed for, the current evidence base, and established PCOS treatment options is essential for making informed decisions about your care.

Understanding Mounjaro and Its Current Approved Uses

Mounjaro (tirzepatide) is a relatively new injectable medication that has generated considerable interest in metabolic medicine. It belongs to a novel class of drugs known as dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. This dual mechanism distinguishes Mounjaro from other medications in the incretin-based therapy family.

In the United Kingdom, Mounjaro received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) in 2023. Its licensed indication is specifically for the treatment of type 2 diabetes mellitus in adults as an adjunct to diet and exercise. It can be used as monotherapy when metformin is inappropriate, or in combination with other antidiabetic medicines. The medication works by mimicking the action of two naturally occurring hormones that help regulate blood glucose levels, enhance insulin secretion when glucose is elevated, and slow gastric emptying.

Clinical trials have demonstrated that Mounjaro produces significant improvements in glycaemic control, with many patients achieving substantial reductions in HbA1c levels. Additionally, the medication has been associated with considerable weight loss, which has attracted attention beyond its primary diabetes indication. Mounjaro is administered once weekly via subcutaneous injection, with dosing typically starting at 2.5 mg and potentially increasing to a maximum of 15 mg based on individual response and tolerability.

It is crucial to understand that whilst Mounjaro has shown promise in various metabolic conditions, its use outside the approved indication for type 2 diabetes constitutes off-label prescribing. This means that any use for conditions such as polycystic ovary syndrome (PCOS) would not be covered by the current marketing authorisation and would require careful consideration by prescribing clinicians.

Importantly, Mounjaro is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception while taking tirzepatide and should stop the medication at least two months before a planned pregnancy.

The Link Between PCOS and Metabolic Health

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age, with an estimated prevalence of 8-13% according to the international PCOS guidelines. Whilst PCOS is often recognised for its reproductive manifestations—including irregular menstrual cycles, anovulation, and polycystic ovarian morphology on ultrasound—the condition has profound metabolic implications that extend far beyond fertility concerns.

Insulin resistance is a central feature of PCOS, present in approximately 50–70% of affected women regardless of body weight. This metabolic dysfunction creates a cascade of hormonal imbalances: elevated insulin levels stimulate ovarian androgen production, contributing to hyperandrogenism (excess male hormones) and the characteristic symptoms of hirsutism, acne, and male-pattern hair loss. The insulin resistance also increases the risk of developing type 2 diabetes, with women with PCOS having a two- to five-fold increased risk compared to the general population.

Weight management presents a particular challenge in PCOS. Many women with the condition struggle with obesity or find weight loss difficult due to the underlying metabolic dysfunction. Excess weight further exacerbates insulin resistance, creating a self-perpetuating cycle. Even modest weight loss of 5–10% of body weight can significantly improve metabolic parameters, restore ovulatory function, and reduce cardiovascular risk factors.

The metabolic syndrome—characterised by central obesity, dyslipidaemia, hypertension, and impaired glucose tolerance—is substantially more prevalent in women with PCOS. This clustering of cardiovascular risk factors means that PCOS should be viewed not merely as a reproductive disorder but as a lifelong metabolic condition requiring comprehensive management and cardiovascular risk assessment.

Women with PCOS who experience infrequent or absent periods (oligomenorrhoea or amenorrhoea) are at increased risk of endometrial hyperplasia and, potentially, endometrial cancer due to unopposed oestrogen action. Regular endometrial protection is therefore an important aspect of PCOS management.

Current Regulatory Status: Is Mounjaro Approved for PCOS in the UK?

The straightforward answer is no—Mounjaro is not currently approved for the treatment of PCOS in the United Kingdom. The MHRA has granted marketing authorisation for Mounjaro solely for type 2 diabetes mellitus in adults. There is no official regulatory approval from the MHRA, the European Medicines Agency (EMA), or other major regulatory bodies for using tirzepatide specifically to treat polycystic ovary syndrome.

This regulatory position is important for several reasons. Firstly, it means that the manufacturer has not submitted—or has not yet received approval for—clinical trial data specifically demonstrating safety and efficacy in PCOS populations. Secondly, prescribing Mounjaro for PCOS would constitute off-label use, which whilst legal in the UK, places additional responsibility on the prescribing clinician to justify the decision based on available evidence and individual patient circumstances.

NICE Clinical Knowledge Summary (CKS) for PCOS does not currently include Mounjaro or other GLP-1/GIP agonists in its recommendations for PCOS management. NICE has published comprehensive guidance on the diagnosis and management of PCOS, but this focuses on established treatment approaches including lifestyle modification, metformin for metabolic features, and various hormonal therapies for specific symptoms.

It is worth noting that the regulatory landscape for medications can evolve as new evidence emerges. Other GLP-1 receptor agonists, such as liraglutide (Saxenda), have gained approval for weight management in specific circumstances, though again not specifically for PCOS. Patients interested in novel therapies should be aware that off-label prescribing may have implications for NHS funding and availability, and may involve private prescribing costs. Any use of Mounjaro for PCOS would require careful discussion with a specialist familiar with both the condition and the medication's properties.

Emerging Research on GLP-1 and GIP Agonists for PCOS Management

Whilst Mounjaro lacks regulatory approval for PCOS, there is growing scientific interest in the potential role of incretin-based therapies for this condition. The rationale is compelling: given that insulin resistance is central to PCOS pathophysiology, medications that improve insulin sensitivity and promote weight loss could theoretically address multiple aspects of the syndrome simultaneously.

Research on GLP-1 receptor agonists (the predecessor class to dual GLP-1/GIP agonists like Mounjaro) has shown promising results in PCOS populations. Several small randomised controlled trials have demonstrated that liraglutide can improve menstrual regularity, reduce body weight, and improve metabolic parameters in women with PCOS. A 2022 systematic review and meta-analysis found that GLP-1 receptor agonists produced significant weight loss and improvements in some metabolic markers in women with PCOS, though the quality of evidence was rated as moderate.

Specific research on tirzepatide in PCOS is still in relatively early stages. The dual mechanism of action—targeting both GIP and GLP-1 receptors—has produced superior weight loss outcomes compared to GLP-1 agonists alone in diabetes trials, which has generated interest in its potential for PCOS. However, there is currently limited published data from large-scale, randomised controlled trials specifically examining tirzepatide's effects on PCOS symptoms, hormonal profiles, or reproductive outcomes.

Several clinical trials are underway investigating GLP-1 and dual agonists in PCOS populations (e.g., NCT04502082), examining outcomes such as metabolic parameters, weight loss, menstrual regularity, and fertility. Until these studies are completed and published in peer-reviewed journals, there is insufficient evidence to draw definitive conclusions about efficacy or safety. Healthcare professionals and patients should be cautious about extrapolating results from diabetes or obesity trials to PCOS populations, as the hormonal and reproductive aspects of PCOS require specific investigation.

Women of childbearing potential should note that tirzepatide and other GLP-1/GIP agonists are not recommended during pregnancy, and effective contraception should be used during treatment.

Established Treatment Options for PCOS in the UK

Women with PCOS have access to several evidence-based treatment options through the NHS, tailored to individual symptoms and priorities. NICE Clinical Knowledge Summary (CKS) recommends a holistic approach beginning with lifestyle modification as first-line management for all women with PCOS, regardless of body weight.

Lifestyle interventions form the cornerstone of PCOS management. Even modest weight loss of 5–10% can significantly improve insulin sensitivity, restore menstrual regularity, and reduce cardiovascular risk. NICE recommends that women with PCOS and a BMI above 25 kg/m² should be offered structured weight management programmes. A balanced, sustainable dietary approach and regular physical activity are recommended to improve insulin sensitivity.

Metformin is commonly prescribed for metabolic aspects of PCOS. This insulin-sensitising agent can improve insulin resistance, support modest weight loss, and reduce the risk of developing type 2 diabetes. Whilst metformin is not licensed specifically for PCOS in the UK, NICE guidance supports its use, particularly in women with glucose intolerance. It may help improve menstrual regularity but is not first-line for ovulation induction. Common side effects include gastrointestinal disturbance, which can often be minimised by using modified-release formulations and gradual dose titration.

For menstrual irregularity and contraception, combined oral contraceptive pills are frequently prescribed. These regulate menstrual cycles and can reduce androgen-related symptoms such as hirsutism and acne. Women with infrequent or absent periods should have endometrial protection, either through hormonal contraception or progestogen-induced withdrawal bleeds at least every 3 months, to prevent endometrial hyperplasia.

Anti-androgen medications like spironolactone may be added for persistent hirsutism. Spironolactone requires effective contraception as it is teratogenic and contraindicated in pregnancy. Cyproterone acetate should be reserved for severe cases and used at the lowest effective dose for the shortest duration due to a dose-dependent risk of meningioma, as highlighted in MHRA safety updates.

Fertility treatment options include ovulation induction for women trying to conceive. Letrozole is generally considered first-line for ovulation induction in PCOS, with clomifene citrate as an alternative. These treatments require specialist oversight. Referral to specialist fertility services may be appropriate if first-line treatments are unsuccessful.

For all women with PCOS, regular monitoring of cardiovascular risk factors, glucose tolerance, and mental health is essential, as PCOS is associated with increased rates of anxiety and depression.

If you experience any suspected side effects from medications, report them through the MHRA Yellow Card Scheme.

What to Discuss with Your Healthcare Provider

If you have PCOS and are interested in emerging treatments like Mounjaro, having an informed conversation with your healthcare provider is essential. Prepare for your appointment by documenting your current symptoms, previous treatments tried, and specific concerns about your condition. Be clear about which aspects of PCOS are most troublesome—whether metabolic issues, menstrual irregularity, fertility concerns, or androgen-related symptoms—as this will help guide treatment decisions.

Questions to consider asking include: What are the most appropriate evidence-based treatments for my specific PCOS symptoms? Would I benefit from referral to an endocrinologist or specialist PCOS clinic? What are the risks and benefits of off-label medications versus established treatments? If weight management is a priority, what structured support programmes are available through the NHS?

It is important to discuss your cardiovascular and metabolic risk. Ask about screening for type 2 diabetes, lipid profiles, and blood pressure monitoring. Women with PCOS should typically have glucose tolerance testing every 1-3 years, depending on risk factors, as recommended by NICE CKS and international PCOS guidelines. Discuss whether your current treatment plan adequately addresses long-term health risks beyond immediate symptom management.

If you are considering off-label treatments like Mounjaro, have an honest discussion about the evidence base, potential benefits, risks, and costs. Off-label prescribing may not be funded through standard NHS pathways, and private prescriptions can be expensive. Your GP or specialist can explain whether there are clinical trials you might be eligible for, which would provide access to novel treatments under supervised research conditions.

If you are of childbearing potential, discuss contraception needs, particularly if considering treatments like GLP-1/GIP agonists or anti-androgens that require effective contraception. If planning pregnancy, discuss medication washout periods (at least two months before planned conception for tirzepatide).

When to seek urgent advice: Contact your GP promptly if you experience severe pelvic pain, sudden changes in menstrual bleeding patterns, heavy bleeding causing dizziness or anaemia symptoms, signs of diabetes (excessive thirst, frequent urination, unexplained weight loss), suspected pregnancy while on medications, or symptoms of depression or anxiety. PCOS requires ongoing management, and regular review appointments ensure your treatment plan remains appropriate as your circumstances and priorities change over time.

Frequently Asked Questions